Sector: MedicalExelixis, Inc. (NASDAQ: EXEL)
Headlines
- Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference
Nov 04, 2009 06:00 AM | BMY, EXEL, SNY
- Ligand Updates License Agreement with Exelixis
Nov 02, 2009 08:30 AM | EXEL, LGND
- Exelixis Announces Third Quarter 2009 Financial Results
Oct 29, 2009 04:10 PM | BMY, EXEL, GSK, SNY
- Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
Oct 23, 2009 06:30 PM | BMY, EXEL
- Exelixis Announces October 29 Webcast of Third Quarter 2009 Financial Results Conference Call
Oct 14, 2009 06:00 AM | EXEL
- RidgewaterEquity.com Free Fundamental Sector & Market Research on DVA, VFC, WYNN, CERN, EXEL and VPHM
Oct 12, 2009 07:11 AM | CERN, DVA, EXEL, VFC, WYNN
- Griffin Securities Announces Investment Opinion on Targeting Cancer Stem Cells
Oct 09, 2009 09:11 AM | BMY, CRIS, EXEL, INFI, KERX
- NeuroTherapeutics Pharma Appoints Dr. Corey Goodman to Its Board of Directors
Oct 05, 2009 08:11 AM | EXEL, PFE
- BioPharm America(TM) 2009 in San Francisco Sets New Benchmark for Partnering Productivity in the US
Sep 23, 2009 01:59 PM | EXEL
- Early Bird Registration Deadline Extended for California Healthcare Policy Forum
Sep 21, 2009 03:31 PM | EXEL, GILD, SNY
- Revlon, General Motors, Palm are big movers
May 28, 2009 06:53 PM | COST, EXEL, GM, M, MCO, PALM
- Big Deals to Reshape Bay Area Biotech
Mar 12, 2009 08:51 PM | AFFY, CVTX, DNA, EXEL, GILD, JEF
- Big Deals Reshape Bay Area Biotech Industry
Mar 12, 2009 11:51 AM | AFFY, CVTX, DNA, EXEL, GILD, PFE
- Mead Johnson Sales Push 4q Profit
Jan 28, 2009 11:57 PM | EXEL, LLY
- Plavix sales help Bristol-Myers swing to Q4 profit - Jan 27 2009 7:20PM
Jan 27, 2009 07:20 PM | BMY, EXEL, LLY
- Plavix sales help Bristol-Myers swing to Q4 profit - Jan 27 2009 11:45AM
Jan 27, 2009 11:45 AM | BMY, EXEL, LLY
- Exelixis Announces August 11 Webcast of Presentation at the Canaccord Adams 29th Annual Global Growth Conference
Aug 07, 2009 05:54 PM | EXEL
- Exelixis Announces Second Quarter 2009 Financial Results
Jul 30, 2009 04:23 PM | EXEL
- Exelixis Announces July 30 Webcast of Its Second Quarter 2009 Financial Results Conference Call
Jul 16, 2009 06:05 AM | EXEL
- Exelixis Announces June 24 Webcast of Presentation at the Piper Jaffray Europe Conference
Jun 16, 2009 04:16 PM | EXEL
- Exelixis Announces June 9 Webcast of Presentation at the Goldman Sachs Thirtieth Annual Healthcare Conference
Jun 04, 2009 06:03 AM | EXEL
- Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR
Jun 01, 2009 02:03 PM | EXEL
- Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K
Jun 01, 2009 01:31 PM | EXEL
- Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme
May 31, 2009 08:01 AM | EXEL
- Exelixis Reports Encouraging Phase 1 Data to Be Presented at ASCO for XL228, a Multi-Targeted Inhibitor of Key Cancer Signaling Kinases
May 30, 2009 04:16 PM | EXEL
- Exelixis and Sanofi-aventis Sign Global License Agreement for XL147 & XL765 and Launch Broad Collaboration for Discovery of PI3K Inhibitors
May 28, 2009 01:01 AM | EXEL
- Form 4 Heller Frances K For: Nov 02 (10K)
Nov 04, 2009 05:43 PM
- Form 4 Lamb Peter For: Aug 04 (10K)
Aug 06, 2009 09:37 PM
- Form 4 RIVERA LUPE M For: Aug 04 (10K)
Aug 06, 2009 09:33 PM
- Form 4 Schwab Gisela For: Jun 03 (10K)
Jun 05, 2009 06:31 PM
- Form 4 Heller Frances K For: Jun 03 (10K)
Jun 05, 2009 06:29 PM
- Form 4 Garber Alan M For: May 14 (10K)
May 14, 2009 07:14 PM
- Form 4 WYSZOMIERSKI JACK L For: May 14 (10K)
May 14, 2009 07:14 PM
- Form 4 MCCORMICK FRANK For: May 14 (10K)
May 14, 2009 07:13 PM
- Form 4 FELDBAUM CARL B For: May 14 (10K)
May 14, 2009 07:10 PM
- Form 4 POSTE GEORGE For: May 14 (10K)
May 14, 2009 07:09 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
EXEL
|
Compare to S&P
|
| YTD |
21.12 %
|
5.58 %
|
| 4 Weeks |
1.50 %
|
0.43 %
|
| 12 Weeks |
9.16 %
|
6.45 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 33.33 %
|
|
EPS Growth in Last Year: 43.59 %
|
|
Sales Growth in Last Quarter: 100.63 %
|
|
Sales Growth in Last Quarter: 83.67 %
|
|
